RS BioTherapeutics has filed a notice of an exempt offering of securities to raise $10 Million in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, RS BioTherapeutics is raising $10,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Dean Hart played a key role…
